Literature DB >> 24529282

Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer.

Ángel Borque1, Jose Rubio-Briones, Luis M Esteban, Gerardo Sanz, Jose Domínguez-Escrig, Miguel Ramírez-Backhaus, Ana Calatrava, Eduardo Solsona.   

Abstract

OBJECTIVES: To implement the use of nomograms in clinical practice showing how to choose thresholds in nomograms' predictions to select risk groups. To validate and compare the predictive ability and clinical utility of the Hospital Universitario 'Miguel Servet' (HUMS) and the updated Partin Tables 2012 (PT-2012) nomograms to predict organ-confined disease (OCD) after radical prostatectomy (RP). PATIENTS AND METHODS: Cohort of 1285 patients with prostate cancer treated with RP at Instituto Valenciano de Oncología (IVO) between 1986 and 2011. The predictive value of the nomograms was assessed by means of calibration curves, discrimination ability (area under the receiver operating characteristic (ROC) curve (AUC) and probability density functions). The clinical utility was evaluated through Vickers' decision curves and thresholds were chosen through probability density functions.
RESULTS: The calibration curves showed a minimal underestimation in low probabilities (<20%), a minimal overestimation in high probabilities (>50%) in the HUMS nomogram and a regular minimal overestimation in the PT-2012. Their AUC of 0.7285 (95% confidence interval [CI] 0.7010-0.7559) and 0.7288 (95%CI 0.7013-0.7562) respectively, show an adequate discrimination ability for both predictive models in the IVO cohort. The decision curves show similar net benefits for both models. In this study we advocate for a threshold of 53% for the identification of OCD.
CONCLUSIONS: The HUMS-nomogram and the PT-2012 predictions of OCD confirm their utility in a contemporary cohort of patients. Patients with a probability of OCD >53% should be classified as OCD, helping physicians to better counsel their patients. A selection of adequate thresholds, as presented in this paper, makes nomograms more accessible tools.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  nomograms; organ-confined disease; prostate cancer; thresholds; validation

Mesh:

Substances:

Year:  2014        PMID: 24529282     DOI: 10.1111/bju.12532

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.

Authors:  Jose López-Torrecilla; Anna Boladeras; María Angeles Cabeza; Almudena Zapatero; Josep Jove; Luis M Esteban; Ivan Henriquez; Manuel Casaña; Carmen González-San Segundo; Antonio Gómez-Caamaño; Jose Luis Mengual; Asunción Hervás; Julia Luisa Muñoz; Gerardo Sanz
Journal:  Strahlenther Onkol       Date:  2015-07-09       Impact factor: 3.621

2.  How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies.

Authors:  Ángel Borque-Fernando; Luis Mariano Esteban; Ana Celma; Sarai Roche; Jacques Planas; Lucas Regis; Inés de Torres; Maria Eugenia Semidey; Enrique Trilla; Juan Morote
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

3.  The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry.

Authors:  Ángel Borque-Fernando; José Rubio-Briones; Luis Mariano Esteban; Argimiro Collado-Serra; Yoni Pallás-Costa; Pedro Ángel López-González; Jorge Huguet-Pérez; José Ignacio Sanz-Vélez; Jesús Manuel Gil-Fabra; Enrique Gómez-Gómez; Cristina Quicios-Dorado; Lluis Fumadó; Sara Martínez-Breijo; Juan Soto-Villalba
Journal:  Oncotarget       Date:  2017-10-24

4.  Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.

Authors:  Catherine Handy Marshall; Wei Fu; Hao Wang; Alexander S Baras; Tamara L Lotan; Emmanuel S Antonarakis
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-08-31       Impact factor: 5.554

5.  Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma.

Authors:  Xiaohan Zhou; Chengdong Liu; Hanyi Zeng; Dehua Wu; Li Liu
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

6.  Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.

Authors:  Jose Rubio-Briones; Angel Borque; Luis M Esteban; Juan Casanova; Antonio Fernandez-Serra; Luis Rubio; Irene Casanova-Salas; Gerardo Sanz; Jose Domínguez-Escrig; Argimiro Collado; Alvaro Gómez-Ferrer; Inmaculada Iborra; Miguel Ramírez-Backhaus; Francisco Martínez; Ana Calatrava; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2015-09-11       Impact factor: 4.430

Review 7.  RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer-From Cell Line Models to Liquid Biopsies.

Authors:  Marvin C J Lim; Anne-Marie Baird; John Aird; John Greene; Dhruv Kapoor; Steven G Gray; Ray McDermott; Stephen P Finn
Journal:  Diagnostics (Basel)       Date:  2018-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.